MX2022006299A - Proteína inmunogénica contra una infección gonocócica. - Google Patents

Proteína inmunogénica contra una infección gonocócica.

Info

Publication number
MX2022006299A
MX2022006299A MX2022006299A MX2022006299A MX2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A MX 2022006299 A MX2022006299 A MX 2022006299A
Authority
MX
Mexico
Prior art keywords
immunogenic protein
protein against
gonococcal infection
against gonococcal
seq
Prior art date
Application number
MX2022006299A
Other languages
English (en)
Spanish (es)
Inventor
Kate Seib
Original Assignee
Univ Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904450A external-priority patent/AU2019904450A0/en
Application filed by Univ Griffith filed Critical Univ Griffith
Publication of MX2022006299A publication Critical patent/MX2022006299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
MX2022006299A 2019-11-25 2020-11-20 Proteína inmunogénica contra una infección gonocócica. MX2022006299A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019904450A AU2019904450A0 (en) 2019-11-25 Immunogenic protein against gonococcal infection
PCT/AU2020/051257 WO2021102505A1 (en) 2019-11-25 2020-11-20 Immunogenic protein against gonococcal infection

Publications (1)

Publication Number Publication Date
MX2022006299A true MX2022006299A (es) 2023-01-19

Family

ID=76128579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006299A MX2022006299A (es) 2019-11-25 2020-11-20 Proteína inmunogénica contra una infección gonocócica.

Country Status (10)

Country Link
US (1) US12479892B2 (https=)
EP (1) EP4065595A4 (https=)
JP (2) JP7825273B2 (https=)
KR (1) KR20220152402A (https=)
CN (1) CN115348968A (https=)
AU (1) AU2020390430A1 (https=)
BR (1) BR112022010167A2 (https=)
CA (1) CA3162559A1 (https=)
MX (1) MX2022006299A (https=)
WO (1) WO2021102505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
JP2024526293A (ja) * 2021-07-05 2024-07-17 エヴァクシオン・バイオテック・アクティエセルスカブ 淋菌を標的とするワクチン
WO2025196270A1 (en) 2024-03-22 2025-09-25 Limmatech Biologics Ag Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
JP6687597B2 (ja) * 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
MX2017015404A (es) * 2015-06-02 2018-05-22 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
CN106606775A (zh) 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
US12109259B2 (en) * 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae

Also Published As

Publication number Publication date
EP4065595A4 (en) 2023-12-20
EP4065595A1 (en) 2022-10-05
US20230181709A1 (en) 2023-06-15
KR20220152402A (ko) 2022-11-15
JP2023503963A (ja) 2023-02-01
US12479892B2 (en) 2025-11-25
CN115348968A (zh) 2022-11-15
JP7825273B2 (ja) 2026-03-06
AU2020390430A1 (en) 2022-07-14
BR112022010167A2 (pt) 2022-08-09
JP2026021348A (ja) 2026-02-10
CA3162559A1 (en) 2021-06-03
WO2021102505A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
MX2022006299A (es) Proteína inmunogénica contra una infección gonocócica.
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
EP2670434A2 (en) Treatment of tauopathies
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
TW200744642A (en) Novel peptides for use in the treatment of obesity
EA201790858A2 (ru) Лечение и профилактика амилоидоза
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP4242294A3 (en) B. amyloliquefaciens strain and therapeutic use
EP4527458A3 (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
MX369195B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
CO2021017664A2 (es) Péptidos
MX2019002248A (es) Proteina de union al factor h modificada.
BR112023024546A2 (pt) Métodos de tratamento usando peptídeos imunogênicos
EP4233912A3 (en) Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
WO2020053742A3 (en) Anti-hla-hbv peptide antibodies
CY1115541T1 (el) Μεταλλαγμενη πρωτεϊνη τατ ουι για την προληψη ή την θεραπευτικη αντιμετωπιση του αids
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
BR102018008420A2 (pt) peptídeos modificados da peçonha da vespa social parachartergus fraternus e seu uso no tratamento de doenças neurodegenerativas
DE602006012065D1 (de) Zusammensetzungen und methoden zur diagnose und behandlung von entzündungen
WO2019157188A3 (en) Compositions and methods for cross-protection against pneumococcal disease